在患有中央血清性胆色素变异症的患者中,氨酸治疗的效果
Fuat Yavrum1, Nedime Sahinoglu-Keskek1
1Ophthalmology, Faculty of Medicine, Alanya Alaaddin Keykubat University, Antalya, TUR.
Cureus
|January 31, 2025
概括
口服黑激素治疗在慢性中央血清性胆色素变异症 (CSCR) 患者中改善视力和胆管血管性方面表现有前途. 这种安全的治疗选择可以提高视力敏度,并调节CSCR患者的眼睛结构.
科学领域:
- 眼科医生 眼科 眼科
- 视网膜疾病 视网膜疾病
- 药理学 药理学是指药理学的学科.
背景情况:
- 慢性中央血清性胆色素变异症 (CSCR) 是一种影响视力的疾病.
- 目前对CSCR的治疗方法有局限性.
- 黑素的抗氧化和抗炎性质表明了潜在的治疗益处.
研究的目的:
- 评估口服黑激素在慢性CSCR患者改善视觉敏度和视网膜/胸膜结构方面的疗效.
- 评估黑激素对中部黄斑厚度 (CMT),中部胆道厚度 (CCT) 和胆道血管度指数 (CVI) 的影响.
主要方法:
- 一项随机对照试验,涉及14名慢性CSCR患者.
- 八名患者每晚接受3毫克口服黑激素;六人作为对照.
- 最好的校正视敏度 (BCVA),CMT,CCT和CVI在基线和一个月后被测量.
主要成果:
- 与一月后的对照组相比,黑素组显示出显著改善的BCVA (p = 0.006) 和降低的CVI (p = 0.01).
- 两组人都在CMT和CCT方面有所改善.
- 在黑激素治疗组 (p = 0.01) 中观察到CVI显著下降 (p = 0.01).
结论:
- 口服メラトニン療法似乎是對CSCR的安全且可能有效的治療方法.
- 在CSCR患者中,黑素可以改善视觉敏度并改变胆道血管动力学.
- 建议对更大的队列和更长的随访进行进一步的研究.
关键词:
中央血清胆色素变异症 (Central Serous Chorioretinopathy) 是一种血清胆色素变异症.冠状腺标记物 冠状腺标记物冠状动脉血管度指数 冠状动脉血管度指数胆管腺体的多模式成像通过口服服用的黑激素.更多相关视频
相关概念视频
Management of Insomnia
229
The sleep cycle, an integral part of human health, consists of several stages with distinct characteristics and functions. It begins with a transition from wakefulness to sleep, known as the light sleep phase, followed by the restorative deep sleep phase, essential for physical recovery and growth. The cycle concludes with the Rapid Eye Movement (REM) phase, characterized by high brain activity and vivid dreaming. Insomnia, a prevalent sleep disorder, involves difficulty falling asleep, staying...
229
Open Angle Glaucoma: Treatment
387
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
387


